Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors

In our four-decade single-center experience of active surveillance for clinical stage I seminoma and nonseminomatous germ cell tumors, reduced surveillance intensity was not associated with change in relapse rates, disease extent, treatment, or outcomes upon relapse. We feel that our reduced intensity schedules are sufficiently safe.